Intersection · Compounds × SURPASS programme

Compounds topics tagged SURPASS programme

Topics in Compounds carrying the tag SURPASS programme. Tirzepatide type 2 diabetes trials.

23 topics

Topic	Participants	Replies	Views	Activity
What the GIP component of tirzepatide is thought to contribute, and how confident we can be tirzepatide SURPASS programme SURMOUNT programme effect size Solved What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl…	+16	20	23k	19h
Tirzepatide storage and stability: what is published versus what is assumed SURPASS programme randomised trial SURMOUNT programme effect size On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read…	+17	21	17k	12d
Does dual agonism explain the effect size, or is it dose? SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…	+62	68	2.6k	29d
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? tirzepatide SURMOUNT programme effect size randomised trial Solved Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J…	+109	122	3.6k	2mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…	+119	136	5.6k	2mo
Reading SURMOUNT-1 without the press release — one year on effect size SURPASS programme randomised trial Solved Closed Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…	+45	50	7.6k	5mo
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? SURMOUNT programme SURPASS programme effect size tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Comparing STEP 2 ( Lancet , 2021) with…	+7	11	281	6mo
Reading SURMOUNT-1 without the press release SURMOUNT programme effect size randomised trial SURPASS programme Posting this under the heading it deserves: Reading SURMOUNT-1 without the press release Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in support of a claim I do not…	+103	121	7k	7mo
Why tirzepatide titration schedules have more steps than semaglutide's SURMOUNT programme SURPASS programme randomised trial tirzepatide Solved Wiki Asking directly, because I could not find a straight answer: Why tirzepatide titration schedules have more steps than semaglutide's Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…		4	8.4k	7mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version SURMOUNT programme randomised trial effect size tirzepatide Closed On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med ,…	+85	90	13k	7mo
Tirzepatide's shorter half-life and its one practical consequence SURPASS programme randomised trial effect size tirzepatide Wiki On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+18	29	20k	8mo
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's tirzepatide SURPASS programme effect size randomised trial Closed Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med ,…	+89	101	32k	8mo
Tirzepatide and nausea: is the profile genuinely different or just differently reported? SURMOUNT programme randomised trial SURPASS programme tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 8 (…	+18	22	37k	8mo
[2026 update] Does dual agonism explain the effect size, or is it dose? SURMOUNT programme randomised trial SURPASS programme effect size Solved Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? Session topic: SELECT ( N Engl J Med , 2023). Please read it before posting; the…	+58	63	40k	9mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med…	+122	136	48k	9mo
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…	+109	124	31k	10mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual SURPASS programme randomised trial effect size SURMOUNT programme Solved SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022)…		4	42k	11mo
Tirzepatide molecular mass and the charge states you would expect on ESI effect size SURPASS programme SURMOUNT programme randomised trial Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…	+36	40	44k	11mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly tirzepatide SURPASS programme randomised trial effect size Solved Closed Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 2 ( Lancet ,…	+150	163	22k	11mo
About the Tirzepatide category tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
SURPASS-2 and the comparator dose question that will not go away SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…	+101	111	1.5k	18mo
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? tirzepatide SURPASS programme effect size The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing…	+15	19	930	18mo
Follow-up: Tirzepatide's shorter half-life and its one practical consequence tirzepatide SURPASS programme SURMOUNT programme effect size Solved Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of…	+130	137	11k	19mo

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →